Blue Jet Healthcare Ltd

Blue Jet Healthcare Ltd has responded to a stock exchange query regarding unusual trading volumes in its securities. The company stated that it has made all necessary disclosures in a timely and transparent manner as required by SEBI Listing Regulations. Blue Jet Healthcare clarified that the significant increase in trading volume is entirely driven by market conditions beyond the company's control. They assured continued adherence to SEBI regulations.

Blue Jet Healthcare Ltd has announced an Extra-Ordinary General Meeting (EGM) scheduled for June 17, 2026, to seek approval for raising funds through the issuance of Equity Shares and/or other Eligible Securities. The meeting will be held via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The notice of the EGM, along with the Explanatory Statement, has been sent electronically to members and is available on the company's website.

Blue Jet Healthcare Ltd's board approved the audited standalone financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.2 (60%) per equity share of face value ₹2. The dividend is subject to shareholder approval at the upcoming Annual General Meeting. The company also approved a proposal to raise funds up to ₹10,000 million through various instruments. Additionally, M/s. HH. Chimthanawala & Co. were re-appointed as Internal Auditors for FY 2026-27.

Blue Jet Healthcare Ltd's board approved audited standalone financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.2 (60%) per share. The company also plans to raise up to ₹31,000 million through various instruments. Additionally, M/s. HH. Chimthanawala & Co. were re-appointed as Internal Auditors for FY 2026-27. An Extra-Ordinary General Meeting is scheduled for June 17, 2026.

Blue Jet Healthcare Ltd's board approved the audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹1.2 (60%) per equity share of face value ₹2. The board also approved a proposal for raising funds up to ₹10,000 million via various instruments. Additionally, M/s. HH. Chimthanawala & Co. were re-appointed as Internal Auditors for FY 2026-27. An Extra-Ordinary General Meeting is scheduled for June 17, 2026.

Blue Jet Healthcare Ltd has scheduled a Board of Directors meeting on May 25, 2026, to approve the audited standalone financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend and a proposal for raising funds through various methods, subject to shareholder and regulatory approvals. The trading window will reopen on May 28, 2026, following a closure period.

Blue Jet Healthcare Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The closure is in accordance with the Company's 'Code of Conduct to Regulate, Monitor and Report Trading in Securities by Insiders of the Company' and SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from April 01, 2026 till 48 hours after the declaration of Audited Standalone Financial Results for the Fourth Quarter and Year ended March 31, 2026. The announcement is also available on the company's website as per the Listing Regulations.

Blue Jet Healthcare marked the ground-breaking of its Vizag manufacturing facility in the presence of Hon’ble Minister for IT, Electronics & Communications and HRD, Shri Nara Lokesh. The Company’s Board of Directors has approved Phase 1 of the project with an investment of approximately 1,000 crore. The facility is envisaged as a multi-phase development with a long-term investment potential of up to 2,300 crore, subject to business milestones, regulatory approvals, and subsequent Board approvals. The Vizag facility will focus on the manufacture of complex pharmaceutical intermediates and active pharmaceutical ingredients (APIs), strengthening Blue Jet Healthcare’s capabilities as a global supplier to pharmaceutical innovators. The project aligns with Andhra Pradesh’s industrial development objectives and supports India’s broader agenda of strengthening advanced manufacturing and supply-chain resilience.

Blue Jet Healthcare Ltd has announced the scheduling of a Groundbreaking Ceremony (Bhoomi Pujan) for a new plot at Industrial Park Rambilli Cluster Phase 11, Anakapalli District, Andhra Pradesh. The ceremony is set to take place on February 28, 2026. This new manufacturing facility is part of the company's growth strategy and will strengthen its infrastructure, helping to meet growing market demands.

Blue Jet Healthcare Ltd held a board meeting on February 13, 2026, and approved the unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The company, which is engaged in manufacturing Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products, reported revenues of INR 192,414 million and INR 689,540 million for the quarter and nine months ended December 31, 2025, respectively. The company does not have any subsidiaries, associates, or joint ventures as of December 31, 2025.